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In order to understand the molecular mechanisms
that underlie the co-evolution of related yet functionally
distinct peptide-receptor pairs, we study receptors for
the vasopressin-related peptide Lys-conopressin in the
mollusc Lymnaea stagnalis. In addition to a previously
cloned Lys-conopressin receptor (LSCPR1), we have
now identified a novel Lys-conopressin receptor sub-
type, named LSCPR2. The two receptors have a differ-
ential distribution in the reproductive organs and the
brain, which suggests that they are involved in the con-
trol of distinct aspects of reproduction and mediate
transmitter-like and/or modulatory effects of Lys-
conopressin on different types of central neurons. In
contrast to LSCPR1, LSCPR2 is maximally activated by
both Lys-conopressin and Ile-conopressin, an oxytocin-
like synthetic analog of Lys-conopressin. Together with
a study of the phylogenetic relationships of Lys-
conopressin receptors and their vertebrate counter-
parts, these data suggest that LSCPR2 represents an
ancestral receptor to the vasopressin/oxytocin receptor
family in the vertebrates. Based on our findings, we
provide a theory of the molecular co-evolution of the
functionally distinct ligand-receptor pairs of the vaso-
pressin/oxytocin superfamily of bioactive peptides.
Peptide receptors form an important subclass of the other-
wise diverse superfamily of G protein-coupled1 receptors that
all have a seven-transmembrane segment topology in common
(for review, see Ref. 1). This receptor type forms a component of
a modular system for the transduction of extracellular signals
across the cell membrane and the subsequent conversion of
these signals to an intracellular second messenger pathway via
the activation of heterotrimeric G proteins (for review, see Ref.
2). Molecular evolutionary mechanisms such as gene duplica-
tion and subsequent mutation of the resulting genes have re-
sulted in the formation of families of related yet distinct pep-
tides (3) and peptide receptors (4). In the nervous and
endocrine systems, many peptide isoforms bind to distinct re-
ceptor subtypes that mediate the specific cellular actions that
underlie a large variety of behavioral and physiological proc-
esses. Peptide-receptor and receptor-effector interactions are of
critical importance for peptide function, and many diseases are
linked to malfunctions of these interactions (5). However, the
great variety in structure of both peptides and receptors has
hampered the development of a coherent theory explaining the
molecular basis of co-evolution of specifically interacting pep-
tide-receptor pairs.
The vasopressin/oxytocin superfamily of peptides and their
cognate receptors offer an attractive model for the study of
specificity of peptide-receptor interactions and the co-evolution
of related peptide-receptor pairs (6). These peptides and recep-
tors occur throughout the entire animal kingdom (for review,
see Ref. 7), allowing detailed comparison of their structural
features and experimental testing of putative specificity deter-
minants. The peptides of the superfamily are surprisingly
alike, sharing at least 5 out of 9 residues and a disulfide-linked
ring structure that put severe constraints on conformational
flexibility (8, 9). In the vertebrates, gene duplication gave rise
to related yet distinct vasopressin and oxytocin genes (10). The
different functions of vasopressin and oxytocin are mediated by
genetically distinct receptor subtypes (11, 12). The V2 vaso-
pressin receptor mediates the antidiuretic effects of vasopres-
sin and couples positively to adenylate cyclase (13–16). By
contrast, the V1a (17, 18) and the V1b (19) vasopressin recep-
tors, which mediate the effects of vasopressin on liver glyco-
genolysis and on adrenocorticotropin release, respectively, as
well as the oxytocin receptor (15, 20, 21), which mediates the
various central and peripheral functions in reproduction of
oxytocin, all couple to the inositol trisphosphate/Ca21 signal
transduction pathway. The discriminative binding of vasopres-
sin and oxytocin to their respective receptors is dictated to a
large extent by the amino acid residue at position 8. At this
position, the family of vasopressin and related peptides have a
basic residue, whereas oxytocin and related peptides have a
neutral, in most cases aliphatic residue (7).
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In the invertebrates, on the other hand, only one gene is
present that is considered the present-day representative of the
ancestral peptide gene to the vasopressin/oxytocin superfamily
(9). In the mollusc Lymnaea stagnalis, this gene encodes Lys-
conopressin, a peptide that is structurally related to vasopres-
sin and that has a wide distribution throughout the inverte-
brate phyla (9, 22–25). In Lys-conopressin, the chemical nature
of the amino acid residue at position 8 is not important for
peptide function, since replacement of this basic residue (ly-
sine) by an aliphatic one (isoleucine) does not affect the potency
of binding of the peptide to its receptor (9). These studies also
show that Lys-conopressin, although structurally related to
vasopressin, controls reproductive functions that are clearly
analogous to the central and myoregulatory functions of oxyto-
cin in vertebrate reproduction. In addition, Lys-conopressin
serves vasopressin-like functions in the control of carbohydrate
metabolism (26). Together, these observations suggest that
functionally distinct vasopressin and oxytocin receptors may
have evolved from a nondiscriminative Lys-conopressin recep-
tor-like receptor by gene duplication and subsequent introduc-
tion of specificity determinants that enable discriminative
binding of vasopressin and oxytocin on the basis of the chemical
nature of amino acid residue 8.
We have recently cloned a Lys-conopressin receptor from the
Lymnaea vas deferens, named L. stagnalis conopressin recep-
tor (LSCPR), that displays discriminative binding properties
with respect to residue 8 in Lys-conopressin (26). Here we
report the cloning of a second Lys-conopressin receptor, named
LSCPR2, that unlike the previously identified receptor (now
renamed LSCPR1), does not discriminate between Lys-
conopressin and its oxytocin-like synthetic analog Ile-conopres-
sin. We show that vasopressin and oxytocin receptors may have
evolved from an LSCPR2-like ancestral receptor, and propose a
mechanism for the molecular evolution of specificity in the
peptide-receptor pairs of the vasopressin/oxytocin superfamily.
Finally, we discuss the role that preexisting receptor subtypes
may have had in the historic development of functionally dis-
tinct vasopressin and oxytocin lineages.
MATERIALS AND METHODS
Animals and Peptides—Adult specimens of L. stagnalis (shell height
28–34 mm), bred in the laboratory under standard conditions (27), were
used. Arg-vasopressin, Arg-vasotocin, Lys-vasotocin, oxytocin, mesoto-
cin, and isotocin were obtained from Saxon Biochemicals (Hannover,
Germany). Lys-conopressin and Arg-conopressin were obtained from
Bachem Feinchemikalien AG (Budendorf, Switzerland). Ile-conopressin
was synthesized as described previously (9).
Cloning and Sequencing of LSCPR2—Poly(A)1 RNA was isolated
from dissected vas deferens of L. stagnalis and reverse transcribed into
oligo-(dT)17-primed cDNA using 200 units of Molony murine leukemia
virus reverse transcriptase (Life Technologies, Inc.). Two degenerate
oligonucleotides, TM6s (59-GGGAATTCG(G/T)N(A/G)(C/T)NTT(C/T)-
N(C/T)N(A/C/T)TNTG(C/T)TGGN(C/T)NCC-39), directed to a conserved
region in TM6 of neuropeptide receptors in general, and TM7as (59-
CCGGATCC(A/G)TA(A/G/T)ATCCANGG(A/G)TT(A/G)CA(A/G)C-39),
directed to a conserved region in TM7 of vasopressin and oxytocin
receptors, were used to amplify vasopressin and oxytocin receptor-like
sequences. The primers contained at the 59-end a recognition sequence
for the restriction endonucleases EcoRI and BamHI, respectively. PCR
was performed in a 100-ml solution containing 10 animal equivalents of
vas deferens cDNA, 200 mM of each of the four deoxynucleotides, 150
pmol of each of the primers TM6s and TM7as, 10 mM Tris-HCl (pH 8.4),
0.1 mg/ml gelatin, 50 mM KCl, 1.5 mM MgCl2, and 2.5 units of Taq DNA
polymerase (Perkin-Elmer Cetus). The PCR mixture was overlaid with
70 ml of mineral oil and incubated in a DNA thermal cycler (Perkin-
Elmer Cetus) for 50 cycles of 1 min at 94 °C, 1 min at 50 °C, and 1 min
at 72 °C. Amplified cDNA fragments were digested with EcoRI and
BamHI and separated on agarose gel, and fragments of the expected
size were isolated, cloned into pBluescript (Stratagene), and sequenced.
One fragment was used to screen several Lymnaea brain-specific
lZAPII cDNA libraries in order to obtain a full-length clone. The insert-
containing pBluescript phagemid corresponding to this clone
(pBSCPR2) was rescued by in vivo excision and sequenced.
Functional Expression of LSCPR2 in Xenopus Oocytes—The protein-
encoding region of pBSCPR2 was amplified using primers directed to
the translation initiation and termination sequences of the cDNA. The
primers contained at the 59-end a recognition sequence for the restric-
tion endonucleases BamHI and EcoRI, respectively. The sense primer
contained the Kozak consensus sequence for transcription initiation
(CCACCATG; Ref. 28) to replace the Lymnaea sequence at this position.
Amplification was carried out in a DNA thermal cycler using 3 units of
Ultma DNA polymerase (Perkin-Elmer Cetus), under conditions recom-
mended by the supplier. Reactions were incubated for 12 cycles of 15 s
at 94 °C, 15 s at 60 °C, and 1.5 min at 72 °C. The cDNA fragment was
digested with BamHI and EcoRI, ligated into pGEMHE (29), and 59-
capped cRNA was transcribed in vitro from a 39-end-linearized plasmid
using 40 units of T7 RNA polymerase and Cap-Scribe transcription
buffer (Boehringer Mannheim). After phenol extraction and ethanol
precipitation, the cRNA was dissolved in bidistilled water, and 50 nl
(;3 ng RNA) was injected into Xenopus laevis oocytes. After incubating
the injected oocytes for 2–3 days at 20 °C (30), two-electrode voltage-
clamped oocytes were challenged with 1.5-min applications of Lys-
conopressin and various related peptides. Peptide-induced membrane
currents were recorded at holding potentials of 250 mV. Dose-response
curves were constructed by integrating the membrane currents over
time and plotting these values (expressed as percentage of the maximal
membrane current) semilogarithmically versus the ligand concentra-
tion. From the mean of three experiments the EC50 value was
calculated.
RT-PCR—Male and female sex organs and glands, kidney, skin,
brain, salivary gland, and hepatopancreas were dissected, and total
RNA was isolated from each tissue in triplicate. Equal amounts of RNA
(3–5 mg for each tissue) were reverse transcribed into oligo-(dT)17-
primed cDNA using 200 units of Molony murine leukemia virus reverse
transcriptase (Life Technologies, Inc.), and of each reaction 5% was
used directly in a PCR experiment. Primers specific for either LSCPR1
or LSCPR2 were used to amplify conopressin receptor cDNAs, and
primers specific for Lymnaea fructose 1,6-biphosphate aldolase2 were
used as a positive control for each cDNA preparation. After 30 cycles of
amplification, PCR products were separated on agarose gel, transferred
to Hybond N1 membrane (Amersham Corp.), hybridized to 59-end 32P-
labeled primers specific for each product, and autoradiographed.
In Situ Hybridization—Digoxigenin-labeled run-off antisense RNA
was synthesized from 59-end-linearized plasmids pBSCPR1 (26) and
pBSCPR2 using 20 units of T3 RNA polymerase and digoxigenin-UTP
labeling mixture (both from Boehringer Mannheim). Hybridizations of
alternately collected sections of Lymnaea brains were performed as
described previously (26).
Phylogenetic Analysis—Sequences of the members of the vasopres-
sin/oxytocin receptor family were extracted from a G protein-coupled
receptor data base (31) and aligned using the program Clustal V (32).
Alignments were adjusted manually, and the transmembrane domains,
as defined by Baldwin (33), were utilized to generate a PAUP data
matrix (34). An accepted mutation stepmatrix was calculated using the
program AMP.3 A branch and bound search was performed without the
stepmatrix, and the three most parsimonious trees with tree lengths of
858 were selected. When the branch and bound search was repeated
with the stepmatrix invoked, one of these trees was found to be the
shortest. Using the PAUP program, 1,000 replicates of bootstrap anal-
ysis were performed using the heuristic search procedure. The calcu-
lated g1 value of 20.869935 (p . 0.01) indicated that relevant phyloge-
netic information was contained within the data set (35).
RESULTS
Cloning of the LSCPR2 cDNA—PCR on vas deferens cDNA
using primers TM6s and TM7as yielded four putative receptor
cDNA fragments. Data base searches revealed that two frag-
ments had significantly higher sequence similarity with the
vertebrate vasopressin and oxytocin receptors than with any
other G protein-coupled receptor. We recently reported the
cloning of the full-length cDNA corresponding to the first frag-
ment (26). Here, we used the second cDNA fragment to screen
brain-specific lZAPII cDNA libraries for full-length clones.
2 R. E. van Kesteren, unpublished results.
3 Provided by K. A. Rice, Harvard University.
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From 4 3 106 independent clones that were screened, one clone
hybridized and was isolated. The corresponding pBluescript
phagemid, named pBSCPR2, was rescued by in vivo excision
and sequenced from both strands. pBSCPR2 has an insert of
4.5 kilobase pairs and contains an open reading frame of 1,560
base pairs encoding a 520-amino acid protein with a predicted
molecular mass of 59.4 kDa (Fig. 1A). The open reading frame
is preceded by an in-frame stop codon at position 245, which
indicates that the coding region is complete at the 59-end.
Structural Characteristics of LSCPR2—Hydrophobicity
analysis (36) of the predicted amino acid sequence revealed 7
hydrophobic domains characteristic for the 7 TMs of G protein-
coupled receptors (Fig. 1B; Ref. 33). Therefore, and because of
its sequence similarity with vasopressin and oxytocin receptors
and with LSCPR1, the predicted protein was tentatively named
L. stagnalis conopressin receptor 2 (LSCPR2). LSCPR2 con-
tains several potential sites for N-linked glycosylation and for
phosphorylation (Fig. 1A). Consensus sequences for N-glyco-
sylation (Asn-X-Ser/Thr; Ref. 37) occur predominantly in the
extracellular N-terminal domain and may have a function in
targeting the receptor protein to the plasma membrane (38).
Consensus sequences for phosphorylation sites (39) include
four sites for protein kinase C (Ser/Thr-X-Arg/Lys), two sites
for casein kinase II (Ser/Thr-X-X-Asp/Glu), and three sites for
cAMP-dependent protein kinase (Arg/Lys-Arg/Lys-X-Ser/Thr).
These are restricted to the third intracellular loop (i.e. between
TM5 and TM6) and the C terminus, suggesting that phospho-
rylation may be important in the modulation of G protein
coupling and receptor function (1).
An amino acid sequence alignment of LSCPR2, LSCPR1, and
FIG. 1. The primary structure of LSCPR2. A, nucleotide sequence and deduced amino acid sequence of clone pBSCPR2. Only the open reading
frame and a part of the 59-untranslated leader sequence are shown. Nucleotides and amino acids are numbered at the right hand side, starting at
the first ATG and the corresponding Met residue. Nucleotides upstream from the first ATG are indicated with negative numbers. An in-frame stop
codon at position 245 is underlined. Putative transmembrane domains in the predicted protein sequence are shown in reversed contrast. Putative
sites for N-linked glycosylation (Asn-X-Ser/Thr) are indicated by asterisks, and putative sites for phosphorylation by protein kinase C (Ser/Thr-
X-Arg/Lys), casein kinase II (Ser/Thr-X-X-Asp/Glu) and cAMP-dependent protein kinase (Arg/Lys-Arg/Lys-X-Ser/Thr) are indicated by dots,
triangles, and daggers, respectively. B, hydrophobicity plot of the LSCPR2 protein according to Kyte and Doolittle (36). Numbers below the figure
indicate amino acid residue positions in the LSCPR2 protein. The seven hydrophobic regions that represent putative transmembrane domains are
shown in black.
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receptors for vasopressin, oxytocin, and vasotocin from verte-
brates is presented in Fig. 2. In the region from the beginning
of TM1 to the end of TM7, LSCPR2 has 43% sequence identity
with the human oxytocin receptor, the rat V1a, and the human
V1b vasopressin receptors and the fish vasotocin receptor, and
39% sequence identity with LSCPR1 and the rat V2 vasopres-
sin receptor. Sequence identity is highest in the transmem-
brane domains, especially in TM7, whereas the N- and C-
terminal domains as well as the third intracellular loop show
hardly any sequence identity.
Several amino acid residues (indicated by asterisks in Fig. 2)
that are conserved only among the members of the vasopressin/
oxytocin receptor family are thought to be important in ligand
binding (6). In LSCPR2, these residues are either identical or
conserved, with the exception of a threonine residue replacing
the glycine residue in the sequence Pro-Trp-Gly (just before
TM5). Interestingly, the two conserved proline residues in the
sequences Gly-Pro-Asp and Pro-Trp-Gly (just before TM3 and
TM5, respectively), which are replaced by aspartate residues in
LSCPR1, are unchanged in LSCPR2.
Two adjacent cysteines that are found 15 residues down-
stream of TM7 in the vasopressin and oxytocin receptors may
be responsible for anchoring the C terminus to the plasma
membrane through palmitoylation, as has been observed for
the b-adrenergic receptor (40). In LSCPR2, there are 4 adjacent
cysteines present 4 residues further downstream. These may
be involved in linking the C terminus of the receptor to the
plasma membrane through a palmitoylation anchor.
Functional Expression of LSCPR2 in Xenopus Oocytes—To
demonstrate that LSCPR2 indeed is a receptor for Lys-
conopressin, we have expressed the LSCPR2 cDNA in Xenopus
oocytes by injection of cRNA and studied the response of in-
jected oocytes upon application of Lys-conopressin and related
peptides. To improve cRNA stability and expression levels in
Xenopus oocytes, the open reading frame of LSCPR2 was
cloned in pGEMHE, between the 59- and 39-untranslated se-
quences of the Xenopus b-globin gene (29). Voltage-clamped
oocytes that were previously injected with 59-capped cRNA
derived from this construct responded to application of cono-
pressins by displaying inward membrane currents (Fig. 3A).
Only application of Lys-conopressin and its synthetic oxytocin-
like analog Ile-conopressin resulted in maximal responses. Arg-
conopressin was about 10 times less potent, and all of the
vertebrate peptides tested had no effects at concentrations as
high as 1026 M. The effects of Lys-conopressin and Ile-conopres-
sin were dose-dependent, with estimated EC50 values of 86 and
96 nM, respectively (Fig. 3B). These values are about four times
higher than observed for LSCPR1 (26).
Differential Expression of the LSCPR1 and LSCPR2 Genes—
Since LSCPR1 and LSCPR2 mRNA levels are undetectable
using Northern blot analysis (data not shown), we applied
RT-PCR to determine possible co-expression of the LSCPR1
and LSCPR2 genes in peripheral tissues and brain. The expres-
sion of both receptor genes is restricted to the brain and the
reproductive organs (Fig. 4). Interestingly, the anterior part of
the vas deferens contains exclusively LSCPR1 mRNA, whereas
the spermoviduct contains exclusively LSCPR2 mRNA. In the
posterior part of the vas deferens, a small amount of both
transcripts was detected. In situ hybridization on alternate
sections of the brain revealed that the two receptor genes are
expressed in mutually exclusive sets of neurons. As reported
previously (26), the LSCPR1 gene is expressed in neurons in
the anterior lobe of the right cerebral ganglion and the pedal Ib
cluster, in a subpopulation of the neuroendocrine light green
cells, and in some unidentified neurons throughout the brain
(not shown). The LSCPR2 gene is predominantly expressed in
neurons in the visceral ganglion (Fig. 5A) and the right parietal
ganglion (Fig. 5B) and in some neurons that are located in close
proximity of the anterior lobes of the cerebral ganglia (Fig. 5C).
Control hybridizations with sense cRNA probes were all
negative.
Phylogenetic Relationships of Lys-Conopressin Receptors and
Their Vertebrate Counterparts—From a sequence alignment of
the transmembrane domains of the members of the vasopres-
sin/oxytocin receptor family, a most parsimonious phylogenetic
tree was calculated. This tree (Fig. 6) has an unweighted tree
FIG. 2. Alignment of the amino acid
sequences of LSCPR2 and members
of the vasopressin/oxytocin receptor
family. The amino acid sequence of
LSCPR2 is aligned with those of LSCPR1
(26), the human oxytocin receptor
(HSOTR; Ref. 20), the rat V1a vasopres-
sin receptor (RNAV1a; Ref. 17), the hu-
man V1b vasopressin receptor (HSAV1b;
Ref. 19), the vasotocin receptor of the te-
leost fish Catostomus commersoni
(CCVTR; Ref. 41), and the rat V2 vaso-
pressin receptor (RNAV2; Ref. 14). Amino
acid residues that are identical in all re-
ceptor proteins are shown in boldface. As-
terisks indicate amino acid residues that
are highly conserved in the vertebrate va-
sopressin/oxytocin receptor family, but
not in other G protein-coupled receptors
and have been suggested to be important
in receptor-ligand interaction (6). Bars in-
dicate the seven putative transmembrane
domains.
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length of 858 and is the best tree found in over 327,128 trees
sampled. It demonstrates that LSCPR1 and LSCPR2 are
clearly related to the vasopressin/oxytocin receptor family of
the vertebrates. Bootstrap analysis of the tree and the data set
show that the assignment of LSCPR1 and LSCPR2 to the
vasopressin/oxytocin receptor clade is supported with over 96%
confidence. These findings strongly suggest that the conopres-
sin receptors and their vertebrate counterparts evolved from a
common ancestral receptor. Moreover, the tree shows that
LSCPR2 is more closely related to the vertebrate receptors
than LSCPR1 and that the separate evolutionary history of
LSCPR1 and LSCPR2 is probably much longer than that of the
vertebrate receptor subtypes.
DISCUSSION
Structure and Functional Expression of LSCPR2—To pro-
vide molecular data for a theory of the co-evolution of peptide-
receptor pairs, we have cloned various Lys-conopressin re-
ceptors in the mollusc L. stagnalis. Using degenerate
oligonucleotides directed to conserved sequences in the mam-
malian vasopressin and oxytocin receptors, we amplified simi-
lar sequences from the vas deferens of Lymnaea. The cloning of
the full-length cDNA corresponding to one of these amplifica-
tion products was recently reported (26). Here, we have used a
second amplification product exhibiting high sequence identity
with vertebrate vasopressin and oxytocin receptors in order to
obtain a full-length cDNA. Hydrophobicity analysis of the pre-
dicted protein sequence of this clone, named LSCPR2, revealed
that it contains seven hydrophobic regions similar to the seven
transmembrane domains found in all members of the G pro-
tein-coupled receptor superfamily. In addition, LSCPR2 con-
tains amino acid residues in the first and second extracellular
loops that are characteristic for the members of the vasopres-
FIG. 3. Functional expression of LSCPR2 in Xenopus oocytes. A, membrane current traces of an oocyte expressing the LSCPR2 protein and
being exposed to 1026 M vasopressin, oxytocin, Arg-conopressin, Lys-conopressin, and Ile-conopressin (indicated by bars). Only application of
conopressins elicited membrane current responses, whereas vasopressin and oxytocin as well as all the other vertebrate peptides tested were
inactive. The initial fast inward current was typically followed by an oscillatory current, which represents intracellular calcium oscillations and
lasted for about 5 min after washing out of the peptide. B, dose-response curves of the effects of Lys-conopressin (black circles) and Ile-conopressin
(open squares) on the total membrane current. The total membrane currents elicited by 1.5-min applications of either of the peptides at different
concentrations were integrated over time and plotted semilogarithmically versus the peptide concentration. The mean of three independent
experiments is shown. The EC50 values are 86 nM for Lys-conopressin and 96 nM for Ile-conopressin.
FIG. 4. Tissue distribution of LSCPR1 and LSCPR2 as deter-
mined by RT-PCR. LSCPR1 and LSCPR2 expression were analyzed
in brain (lane 1), penis complex (lane 2), anterior vas deferens (lane 3),
posterior vas deferens (lane 4), prostate gland (lane 5), spermoviduct
(lane 6), ovotestis (lane 7), albumen gland (lane 8), oothecal gland (lane
9), muciparous gland (lane 10), kidney (lane 11), skin (lane 12), salivary
gland (lane 13), and hepatopancreas (lane 14). The LSCPR1 transcript
could be amplified from the brain and the anterior and posterior vas
deferens, and the LSCPR2 transcript could be amplified from the brain,
the spermoviduct and the posterior vas deferens. Lanes 15 and 16
contain PCR products derived from the LSCPR1 and LSCPR2 clones,
respectively, and serve as positive controls for the PCR and the hybrid-
ization procedure.
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sin/oxytocin receptor family (Fig. 2). LSCPR2 is activated by
Lys-conopressin at physiological concentrations, but not by
other naturally occurring vasopressin- or oxytocin-related pep-
tides (Fig. 3). Together, these data indicate that LSCPR2 is a
functional Lys-conopressin receptor, and that LSCPR1 and
LSCPR2 represent distinct subtypes of Lys-conopressin recep-
tors in Lymnaea.
Compared with the vertebrate receptors, the LSCPR2 pro-
tein has the highest sequence identity with the mammalian
V1a and V1b vasopressin receptors (17, 19), the mammalian
oxytocin receptor (20), and the vasotocin receptor from teleost
fish (41), which all couple to the inositol trisphosphate/Ca21
signaling pathway. Sequence identity with the mammalian V2
vasopressin receptor (13, 14), which is coupled to adenylate
cyclase, is less. Furthermore, Xenopus oocytes expressing the
LSCPR2 protein respond to application of Lys-conopressin by
displaying a dose-dependent inward chloride current (Fig. 3), a
response that is characteristic for receptors that activate the
inositol trisphosphate/Ca21 signal transduction pathway (30).
These findings indicate that most likely LSCPR2 is coupled to
a G protein that activates the inositol trisphosphate/Ca21 sig-
nal transduction pathway. LSCPR1 has similar signal trans-
duction characteristics, however, half-maximal receptor activa-
tion is reached at four times lower concentrations of Lys-
conopressin (26). The first and second extracellular loops of the
vasopressin and oxytocin receptors have been suggested to
form a ligand binding pocket (6). Interestingly, the correspond-
ing loops in LSCPR1 contain two unique aspartate residues
that are absent in LSCPR2 (Fig. 2). Since conopressins differ
from other vasopressin- and oxytocin-related peptides in that
they have a negatively charged arginine residue at position 4
(22), we have suggested that either of these positively charged
aspartate residues may be important in the interaction of
LSCPR1 with this arginine residue (26). The absence of the
aspartate residues in LSCPR2 might explain the fact that this
receptor is less sensitive to Lys-conopressin than LSCPR1.
Differential Expression of Conopressin Receptor Subtypes in
Lymnaea—To investigate the physiological significance of mul-
tiple conopressin receptors in Lymnaea, we compared the pe-
ripheral and neuronal distribution of LSCPR1 and LSCPR2 by
means of RT-PCR and in situ hybridization. The expression of
both receptors is restricted to the reproductive organs and the
brain. LSCPR1 is exclusively expressed in the vas deferens
(Fig. 4) and is involved in the control of muscular activity
during transport of semen (26). LSCPR2 is predominantly ex-
pressed in the spermoviduct, and a small amount of transcript
could be detected in the posterior part of the vas deferens (Fig.
4). In the spermoviduct, both eggs and sperm are transported,
and fertilization of eggs and resorption of unused sperm occur.
Interestingly, Lys-conopressin mRNA could also be detected in
this tissue,4 suggesting that LSCPR2 might mediate auto- or
paracrine actions of Lys-conopressin in the control of any of the
reproductive functions of the spermoviduct. Similarly, vaso-
pressin has been suggested to have an autocrine regulatory role
in Leydig cells of rodent testis (42). Although LSCPR1 and
LSCPR2 transcripts are co-localized in the posterior part of the
vas deferens, the LSCPR1 mRNA detected here is probably
synthesized in central neurons that innervate the vas deferens
(26). The cellular source of LSCPR2 mRNA in the vas deferens
remains unclear. In the brain, co-localization of LSCPR1 and
LSCPR2 transcripts could not be observed.
The differential distribution of the two Lys-conopressin re-
ceptors suggests that they must have different functions. In the
periphery, they are most likely involved in the regulation of
distinct aspects of reproduction, whereas in the brain, they
4 R. E. van Kesteren, unpublished results.
FIG. 5. Localization of LSCPR2 gene expression in the brain by
in situ hybridization. A, section through the visceral ganglion; B,
section through the right parietal ganglion showing two unidentified
neurons, indicated by arrows, that express the LSCPR2 gene; C, section
through the right cerebral ganglion ganglion showing a small group of
unidentified neurons, indicated by arrows, that expresses the LSCPR2
gene. Neither of these neurons was found to express the LSCPR1 gene
(not shown), nor could co-expression of LSCPR1 and LSCPR2 be de-
tected in any other part of the brain. (Magnification, 250X.)
FIG. 6. Phylogenetic relationships of the members of the vaso-
pressin/oxytocin receptor family. Using an accepted mutation
methodology (L. F. Kolakowski, Jr., and K. A. Rice, submitted for
publication), the phylogenetic relationships of LSCPR1, LSCPR2, and
related receptors from vertebrates were analyzed. The most parsimo-
nious tree resulting from these analyses is shown. Numbers above the
branches are the results of a bootstrap analysis and are confidence
limits for the positions of the branches. The abbreviations used are as
follows: V2R, V2 vasopressin receptor; V1aR, V1a vasopressin receptor;
V1bR, V1b vasopressin receptor; VTR, vasotocin receptor; OTR, oxyto-
cin receptor; ITR, isotocin receptor; CPR, conopressin receptor. The
vasotocin receptors from the toad X. laevis and from the teleost fish
Oncorhynchus kisutch, as well as the isotocin receptor from the teleost
fish Astyanax fasciatus, have been cloned partially (41) and are classi-
fied as such on the basis of their positions in the tree. The Bovine
rhodopsin sequence was utilized as an outgroup for the tree.
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probably mediate transmitter-like or modulatory effects of Lys-
conopressin on different types of neurons. A possible explana-
tion for the existence of multiple conopressin receptors is that
it allows a stimulus-dependent differential expression of the
receptor genes in various target tissues and cells, thus provid-
ing a mechanism for a spatio-temporal co-ordination of Lys-
conopressin actions in otherwise conflicting types of behavior
and physiological processes. Similarly, transcriptional regula-
tion of the human oxytocin receptor gene plays an important
role in the physiologically relevant increase in the number of
oxytocin receptors in the uterus of pregnant females at the
onset of labor (20). In addition, the difference in the sensitivity
of the two receptors to Lys-conopressin that we observed may
be physiologically relevant in this respect as well.
Prospects for Understanding the Co-evolution of Specifically
Interacting Peptide-Receptor Pairs—Peptides are extensively
employed as messenger molecules in the various communica-
tion systems that are involved in the control of physiological
processes and behavior (43). These systems, which include
wiring transmission (communication via the synapse), volume
transmission (communication via the intercellular space), hor-
monal transmission (communication via the circulation), and
environmental transmission, emerged at various stages during
evolution. Due to differences in requirements for optimized
information exchange, both peptide design and specificity of
peptide-receptor interactions are under different selection
pressures in the various communication channels (43, 44).
With the evolution of complex organisms such as vertebrates,
many peptides and receptors were recruited into the hormonal
communication channel, thus increasing the demands for spec-
ificity in order to exclude cross-activation of the many different
receptors that can be reached. In view of the great variety in
both size and conformational flexibility of peptides, it seems
plausible that different structural solutions emerged in re-
sponse to the need for specificity of peptide-receptor interac-
tions. Large and flexible peptides such as luteinizing hormone
and follicle-stimulating hormone, which like vasopressin and
oxytocin evolved from a single ancestral gene, have acquired
distinct regions of many amino acid residues that exclude
cross-activation of receptors (45). Consequently, these specific-
ity determinants are mirrored in the luteinizing hormone and
follicle-stimulating hormone receptors at entirely different
locations.
As we have shown, specificity determinants in the small and
conformationally constrainted peptides of the vasopressin/oxy-
tocin superfamily evolved in a different way. Residues 1–6 of
these peptides are important for high affinity binding to the
receptor (26), whereas specific receptor activation depends on
the chemical nature of the single amino acid residue at position
8. In contrast to the development of luteinizing hormone and
follicle-stimulating hormone and their receptors, where sepa-
ration of large specificity domains in both the peptides and the
receptors allowed for a continuous refinement of specificity
during evolution (45), functionally distinct vasopressin and
oxytocin peptides can only have evolved by trial-and-error mu-
tation of residue 8 in the presence of a nondiscriminative re-
ceptor such as LSCPR2. This trial-and-error phase may be
reflected in various present day species of cartilaginous fish.
Unlike the evolutionary stable vasopressin lineage, oxytocin-
like peptides are very diverse in this primitive group of the
vertebrates (7). To none of these peptides has a function been
assigned, and they have very poor uterotonic activity in mam-
mals (46). Hence, it will be of interest to examine whether
functional receptors exist for these peptides. If not, they must
be considered relicts of an early step in the historic develop-
ment of the oxytocin lineage of bioactive peptides.
To further demonstrate that a nondiscriminative LSCPR2-
like receptor may have been ancestral to the vasopressin/oxy-
tocin receptor family, we studied the phylogenetic relationships
of the Lys-conopressin receptors and their vertebrate counter-
parts using parsimony analysis. Phylogenetic reconstruction is
nowadays accepted as a valid method to study the evolutionary
histories of families of related receptors and provides useful
insights into the structures and functions of the individual
members (47).5 Our data indicate that LSCPR2 is indeed more
closely related to the vertebrate vasopressin and oxytocin re-
ceptors than LSCPR1 (Fig. 6). Therefore, LSCPR2 most likely
is a present day representative of the ancestral receptor to the
vertebrate receptors. In addition, the phylogenetic analysis
shows that LSCPR1 and LSCPR2 probably result from an
ancient receptor duplication that occurred before separate re-
ceptor types in the vertebrates evolved. Thus, multiple recep-
tors may have existed before separate lineages of vasopressin-
and oxytocin-related peptides evolved. Since the evolution of
functionally distinct peptide lineages from a common ligand-
receptor pair requires not only the introduction of specificity
determinants on both the peptides and the receptors but also
a differential cellular pattern of expression of distinct recep-
tor types, we suggest that preexistence of differentially ex-
pressed receptor subtypes was of significant importance in
the functional divergence of vasopressin and oxytocin in the
vertebrates.
As in the peptides of the vasopressin/oxytocin superfamily,
specificity determinants in the corresponding receptors are
probably restricted to small parts of the receptor molecules (6).
LSCPR2 can be very useful in the search for these determi-
nants. Experiments involving chimeric receptors and swapping
of putative binding domains might mimmick the evolutionary
process of introducing specificity determinants in a nondis-
criminative ancestral receptor such as LSCPR2, and increase
our understanding of the molecular basis of peptide-receptor
interactions. This then might enable the rational design of
highly potent and specific receptor agonists and antagonists.
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